WHO stops trial of hydroxychloroquine for COVID-19 treatment


The World Health Organisation, WHO, said it has stopped the use of hydroxychloroquine trials for COVID-19 treatment.

In a statement on Saturday via its website, WHO stated that the International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the WHO Summit on COVID-19 research and innovation held on July 12.


Coronavirus: US drug regulator revokes emergency use of hydroxychloroquine and chloroquine

WHO said, “These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.

“For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication.”